Ionis reports fourth quarter and full year 2020 financial results and recent business achievements
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Paradium AI (PAAI) Halted, News Pending
Ionis Pharmaceuticals (IONS) Misses Q4 EPS by $2.72, Revenues Beat; Offers FY21 Revenue Guidance Below Consensus
February 24, 2021 7:11 AM ESTIonis Pharmaceuticals (NASDAQ: IONS) reported Q4 EPS of ($2.44), $2.72 worse than the analyst estimate of $0.28. Revenue for the quarter came in at $290 million versus the consensus estimate of $274.48 million.
"Last year, we laid out a bold new vision for the Company and took important steps towards our goal of becoming one of the most successful biotechnology companies. Key to our vision is our strategy to maximize the value of our pipeline by commercializing our wholly owned medicines. Our acquisition of Akcea was an important step in building our commercial capabilities while enabling us to... More
